Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) EBIT (2019 - 2025)

Historic EBIT for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $362.7 million.

  • CureVac's EBIT fell 1035.93% to $362.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.4 million, marking a year-over-year increase of 2480.14%. This contributed to the annual value of $189.9 million for FY2024, which is 16435.62% up from last year.
  • Per CureVac's latest filing, its EBIT stood at $362.7 million for Q3 2025, which was down 1035.93% from -$69.9 million recorded in Q2 2025.
  • CureVac's EBIT's 5-year high stood at $404.6 million during Q3 2024, with a 5-year trough of -$178.0 million in Q2 2021.
  • Its 5-year average for EBIT is -$32.3 million, with a median of -$64.8 million in 2023.
  • Per our database at Business Quant, CureVac's EBIT plummeted by 187017.13% in 2022 and then skyrocketed by 78775.91% in 2024.
  • Quarter analysis of 5 years shows CureVac's EBIT stood at -$6.3 million in 2021, then tumbled by 1870.17% to -$124.0 million in 2022, then grew by 23.62% to -$94.7 million in 2023, then skyrocketed by 50.57% to -$46.8 million in 2024, then skyrocketed by 874.82% to $362.7 million in 2025.
  • Its last three reported values are $362.7 million in Q3 2025, -$69.9 million for Q2 2025, and -$57.6 million during Q1 2025.